NextCure (NASDAQ:NXTC) Earns Buy Rating from HC Wainwright

NextCure (NASDAQ:NXTC)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $3.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 418.85% from the company’s current price.

NextCure Stock Performance

NXTC opened at $0.58 on Monday. The firm’s fifty day moving average is $0.76 and its two-hundred day moving average is $1.07. The firm has a market cap of $16.19 million, a PE ratio of -0.28 and a beta of 0.71. NextCure has a twelve month low of $0.58 and a twelve month high of $2.57.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). Equities analysts forecast that NextCure will post -1.87 EPS for the current fiscal year.

Institutional Investors Weigh In On NextCure

Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC increased its position in shares of NextCure by 40.6% during the fourth quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after acquiring an additional 22,724 shares in the last quarter. Geode Capital Management LLC increased its position in shares of NextCure by 14.2% during the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock worth $307,000 after acquiring an additional 27,812 shares in the last quarter. Peapod Lane Capital LLC bought a new stake in shares of NextCure during the fourth quarter worth $311,000. Renaissance Technologies LLC increased its position in shares of NextCure by 27.9% during the fourth quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock worth $400,000 after acquiring an additional 113,300 shares in the last quarter. Finally, Tang Capital Management LLC increased its position in shares of NextCure by 7.3% during the fourth quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock worth $540,000 after acquiring an additional 47,614 shares in the last quarter. 42.65% of the stock is currently owned by institutional investors and hedge funds.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.